Pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 10, 1999, Pages 1044-1052

  Zannikos, P N ^a   Baybutt, R I ^a   Boutouyrie, B X ^a   Shah, B ^a   Hunt, T L ^a   Jensen, B K ^a  

^a Drug Safety and Metabolism   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ADENOSINE RECEPTOR STIMULATING AGENT; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; HEADACHE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA;

EID: 0033307237     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922011818     Document Type: Article

References (15)

1. Cardiovascular pharmacology of purines
2. Cardiac electrophysiology and pharmacology of adenosine: Basic and clinical aspects
3. The pharmacology of adenosine
4. Cardiovascular purinoceptors
5. 2 receptor agonist, AMP 579, in a porcine model of myocardial infarction
6. Dipyridamole inhibition of adenosine metabolims in human blood
7. Measurement of adenosine, inosine and hypoxanthine in human plasma
8. Turnover of adenosine in plasma of human and dog blood
9. Pharmacokinetics of exogenous adenosine in man after infusion
10. Harnessing an endogenous cardioprotective mechanism: Cellular sources and sites of action of adenosine
11. 2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart
12. Ischemic preconditioning
13. 2-receptor agonists on myocardial reperfusion injury
14. Physiological parameters in laboratory animals and humans